Format

Send to

Choose Destination
Dement Geriatr Cogn Disord. 2009;27(2):155-63. doi: 10.1159/000199236. Epub 2009 Feb 2.

Effect of oxcarbazepine in the treatment of agitation and aggression in severe dementia.

Author information

1
Innlandet Hospital Trust, Department of Geriatric Psychiatry, Reinsvoll, Norway. oskarsommer@gmail.com

Abstract

BACKGROUND/AIMS:

To evaluate the efficacy of oxcarbazepine (OXC) in the treatment of agitation and aggression in patients with Alzheimer's disease, vascular dementia or both.

METHODS:

This is an 8-week, multicenter, randomized, double-blind, placebo-controlled trial carried out independently of the pharmaceutical industry. Changes in the agitation and aggression subscore of the Neuropsychiatric Inventory (NPI) were the primary outcomes. The secondary out- comes were the changes in the caregivers' total burden scores (measured by the NPI) and changes in the Brief Agitation Rating Scale (BARS).

RESULTS:

In total, 103 institutionalized patients at 35 sites were randomized to the trial. After 8 weeks, no statistically significant differences were found between the 2 groups for all outcomes. A trend was observed in favor of the OXC group in the reduction in the scores on the BARS (p = 0.07).

CONCLUSION:

This study found no significant effect of OXC in treatment of agitation and aggression in patients with dementia.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT00145691.

PMID:
19182483
DOI:
10.1159/000199236
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for S. Karger AG, Basel, Switzerland
Loading ...
Support Center